Evaluation of the safety and tolerability of rivaroxaban in dogs

Thromboembolism is one of the leading causes of morbidity and mortality associated with primary immune-mediate hemolytic anemia (pIMHA). Several veterinary clinical studies have demonstrated improved case outcome when anti-thrombotic therapy is part of the treatment for pIMHA. At least one of those studies revealed that anti-platelet therapy was the only treatment variable in conjunction with prednisone that improved patient survival. Anticoagulants have high risk of complications (bleeding), can be cumbersome for most pet owners to administer, and they require frequent monitoring.
Source: Advances in Small Animal Medicine and Surgery - Category: Veterinary Research Tags: Critical Care Source Type: research